Maxim Group Downgrades Citius Pharmaceuticals (NASDAQ:CTXR) to Hold
Maxim Group cut shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) from a strong-buy rating to a hold rating in a research note released on Friday, MarketBeat.com reports. Separately, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a research report on Thursday, May 15th. […]
Maxim Group cut shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) from a strong-buy rating to a hold rating in a research note released on Friday, MarketBeat.com reports. Separately, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a research report on Thursday, May 15th. […]
